Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma

BACKGROUND: Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor as ≥ fourth-line therapy. We present the efficacy and safety of ripretinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Janku, F., Bauer, S., Shoumariyeh, K., Jones, R.L., Spreafico, A., Jennings, J., Psoinos, C., Meade, J., Ruiz-Soto, R., Chi, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434165/
https://www.ncbi.nlm.nih.gov/pubmed/35753087
http://dx.doi.org/10.1016/j.esmoop.2022.100520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434165/
https://www.ncbi.nlm.nih.gov/pubmed/35753087
http://dx.doi.org/10.1016/j.esmoop.2022.100520

Ejemplares similares